Microbion Corporation to Present Data Highlighting Broad Spectrum Activity of BisEDT

BOZEMAN, Mont., and VANCOUVER, British Columbia, April 15, 2019 /PRNewswire/ -- Microbion Corporation today announced that the company will present data highlighting the broad-spectrum activity of its novel antimicrobial agent BisEDT at the 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which will take place April 13 – 16, 2019 in Amsterdam, Netherlands. BisEDT is the active pharmaceutical ingredient of Microbion's therapeutic formulation MBN-101.

Spotlight

BioMD Genetics Inc.

BioMD Genetics Inc. is a Canadian innovation-driven company that provides human genetic testing solutions to business partners AND personal genetics service directly to consumers and through authorized retailers. We have been constantly innovating and using the best current practices and technologies of human genetics science to provide our clients and customers with the best possible experience. Our highly creative and qualified team, consisting of researchers, practitioners and bioinformatics, ensures that top-quality services are delivered to our clients and customers.

OTHER ARTICLES
Research

5 Biotech Stocks Winning the Coronavirus Race

Article | July 11, 2022

There are quite a few companies that have found ways to grow their business during the ongoing COVID-19 pandemic. This is especially true for a number of biotechs now working on developing a potential treatment for, or vaccine against, the virus; shares of such companies have largely surged over the past couple of months. Although many of these treatments and vaccines are still have quite a way to go before they're widely available, it's still worth taking some time to look through what's going on in the COVID-19 space right now. Here are five biotech stocks that are leading the way when it comes to addressing COVID-19. Regeneron Pharmaceuticals (NASDAQ:REGN) wasn't among the initial wave of companies to announce a potential COVID-19 drug. However, investor excitement quickly sent shares surging when the company announced that its rheumatoid arthritis drug, Kevzara, could help treat COVID-19 patients.

Read More
Medical

2 Small-Cap Biotech Stocks You Haven't Heard of, But Should Know About

Article | August 16, 2022

With everything that's going on with the COVID-19 pandemic, many healthcare companies have grabbed plenty of spotlight during these challenging times. At the same time, a number of otherwise promising businesses have slipped under the radar. That's especially true for small-cap biotech stocks that aren't actively involved in developing tests, vaccines or treatments for COVID-19. Vaccine developers, protective equipment producers, and healthcare service providers are all attracting plenty of attention during this pandemic, but there are just as many promising biotech stocks that aren't involved in these areas. Here are two such companies that you might have missed, but they deserve a spot on your watch list.

Read More
MedTech

Immunology: A New Frontier in Medical Science

Article | October 7, 2022

Introduction Recent developments in the bioengineering of monoclonal antibodies (mAbs) have revolutionized the treatment of numerous rheumatic and immunological disorders. Currently, several immunological disorders are successfully being targeted and treated using innovative medical techniques such as immunotherapy. Leading companies are increasingly investing in research activities to expand the usage and application of immunology for the treatment of various infectious diseases, including multiple sclerosis, inflammatory bowel disorders, lupus, and psoriasis, leading companies are increasingly investing in research activities. Today, the efforts of researchers in immunology, with a long history of study and research, have borne fruit, as bioengineered mAbs are now being employed in clinical practices. Accelerating Investments: Paving the Way for Immunology The increasing prevalence of infectious diseases, cancer, and immune-mediated inflammatory disorders (IMIDs) is raising the need for more precise classification and an in-depth understanding of the pathology underlying these ailments. Numerous leaders in the biotechnology domain are thus focusing on undertaking numerous strategies, such as new facility launches and collaborations, to address the need by finding deeper inroads into immunology and its use in disease treatments. For instance, in 2022, the University of Texas MD Anderson Cancer Center announced the launch of a visionary research and innovation hub, the James P. Allison Institute, to find new roads in immunotherapy, develop new treatments, and foster groundbreaking science. These developments will result in better diagnosis through the use of selective biomarkers, and early detection of fatal diseases and their treatment, which will prevent complications from happening. Also, the identification of high-risk populations through a deeper understanding of genetic and environmental factors can assist in the prevention of disease through immunotherapy. The Way Forward Immunology has led to the development of biotechnology, making it possible to develop novel drugs and vaccines, as well as diagnostic tests, that can be used to prevent, diagnose, and treat a wide range of autoimmune, infectious, and cancerous diseases. With the rapid advancement in technology and the integration of artificial intelligence, immunology is finding its way into an array of domains and industries, encompassing several research areas including medicine, pharmaceuticals, agriculture, and space. Today, not only researchers but also leading biotech and pharmaceutical companies have recognized that conventional therapies with pharmaceutical and chemical products are being replaced by products derived from immunology. This is because they work well for health problems, are environmentally friendly, and are also emerging as a wealth-generating business in the medical field.

Read More
Medical

Advancement in Genomics Accelerating its Penetration into Precision Health

Article | June 22, 2022

Genomics is an interdisciplinary field of biology emphasizing the structure, editing, evolution, function, and mapping of genomes. It is creating deeper inroads across the precision health domain with the increasing introduction of advanced technologies such as quantum simulation, next-generation sequencing (NGS), and precise genome manipulation. As precision health focuses on providing the proper intervention to the right patient at the right time, genomics increasingly finds applications in human and pathogen genome sequencing in clinical and research spaces. Rising Hereditary Diseases Burden Paving the Way for Genomics in Precision Health In the last few years, a significant surge in the prevalence of diseases and ailments such as diabetes, obesity, baldness, and others has been witnessed across the globe. A history of family members with chronic diseases, such as cancer, diabetes, high blood pressure, hearing issues, and heart disease, can sometimes continue into the next generation. Hence, the study of genes is extensively being conducted for predicting health risks and early treatment of these diseases. It also finds use in CRISPR-based diagnostics and the preparation of precision medication for the individual. In addition, ongoing advancements in genomics are making it possible to identify different genetic traits that persuade people to more widespread diseases and health problems. The Emergence of Genomics Improves Disease Understanding Genomics refers to the study of the complete genetic makeup of a cell or organism. Increasing scientific research in the area substantially contributes to increasing knowledge about the human genome and assists in improving the ability to understand disease etiology, risk, diagnosis, treatment, and prevention. On account of these improvements, innovative genomic technologies and tools are being developed to enable better precision health not only for the individual but for various regional populations as well. The Way Forward With growing preference for personalized medicine and an increasing need for more accurate pathogen detection and diagnostics, genomics is gaining huge popularity across the precision health domain. Also, increasing research activities for developing novel high-precision therapeutics and rising importance of gene study in the prevention, diagnosis, and management of infectious and genetic diseases will further pave the way for genomics in the forthcoming years.

Read More

Spotlight

BioMD Genetics Inc.

BioMD Genetics Inc. is a Canadian innovation-driven company that provides human genetic testing solutions to business partners AND personal genetics service directly to consumers and through authorized retailers. We have been constantly innovating and using the best current practices and technologies of human genetics science to provide our clients and customers with the best possible experience. Our highly creative and qualified team, consisting of researchers, practitioners and bioinformatics, ensures that top-quality services are delivered to our clients and customers.

Related News

Severity of COVID-19 May Depend on Your Individual Genetic Variation in Immune System

SciTechDaily | April 19, 2020

Genetic variability in the human immune system may affect susceptibility to, and severity of infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the coronavirus disease (COVID-19). The research is published on April 17, 2020, in the Journal of Virology, a publication of the American Society for Microbiology. Individual genetic variation may explain differences in the strength of immune responses. Certain immune system genes, called human leukocyte antigen genes that are involved in recognizing pathogens, vary from person to person. Variations can influence how well the immune system recognizes a given pathogen. Poor recognition of SARS-CoV-2 could cause a person to be more vulnerable to the virus. “In particular, understanding how variation in HLA [a component of the immune system containing multiple genes] may affect the course of COVID-19 could help identify individuals at higher risk from the disease,” according to the authors of the new study.

Read More

Biotech stocks surge as people are hungry for good news on the coronavirus

cnbc | April 17, 2020

Biotech stocks surged Friday after new details on a closely watched clinical trial lifted hopes that scientists may be close to a treatment for the coronavirus, which continues to maintain its foothold across the globe after emerging a little over three months ago.The IBB, an ETF that tracks biotech’s biggest players, was up more than 2% Friday after health-care publication STAT News revealed early impressions from one of Gilead Sciences’ clinical trials for antiviral drug remdesivir. The University of Chicago found that patients with Covid-19 had “rapid recoveries in fever and respiratory symptoms” and were discharged in less than a week, according to STAT. News that biotech firm Moderna received $483 million in federal funds for its vaccine development also boosted the sector higher.

Read More

Selected Notes From Wall Street Analysts On Applied DNA Sciences, Inc. (APDN)

US Post News | April 16, 2020

On Wednesday, shares of Applied DNA Sciences, Inc. (NASDAQ:APDN) marked $5.76 per share versus a previous $4.55 closing price. With having a 26.59% gain, an insight into the fundamental values of Applied DNA Sciences, Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. APDN showed a rise of 37.47% within its YTD performance, with highs and lows between $2.52 – $33.60 during the period of 52 weeks, compared to the simple moving average of -26.60% in the period of the last 200 days. Maxim Group equity researchers changed the status of Applied DNA Sciences, Inc. (NASDAQ: APDN) shares to a “Buy” rating in the report published on November 14th, 2016. Other analysts, including Maxim Group, also published their reports on APDN shares. Maxim Group repeated the rating from the previous report, marking APDN under “Buy” rating, in the report published on May 13th, 2016. Additionally, APDN shares got another “Buy” rating from Maxim Group, setting a target price of $13 on the company’s shares, according to the report published in October 8th, 2015.

Read More

Severity of COVID-19 May Depend on Your Individual Genetic Variation in Immune System

SciTechDaily | April 19, 2020

Genetic variability in the human immune system may affect susceptibility to, and severity of infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the coronavirus disease (COVID-19). The research is published on April 17, 2020, in the Journal of Virology, a publication of the American Society for Microbiology. Individual genetic variation may explain differences in the strength of immune responses. Certain immune system genes, called human leukocyte antigen genes that are involved in recognizing pathogens, vary from person to person. Variations can influence how well the immune system recognizes a given pathogen. Poor recognition of SARS-CoV-2 could cause a person to be more vulnerable to the virus. “In particular, understanding how variation in HLA [a component of the immune system containing multiple genes] may affect the course of COVID-19 could help identify individuals at higher risk from the disease,” according to the authors of the new study.

Read More

Biotech stocks surge as people are hungry for good news on the coronavirus

cnbc | April 17, 2020

Biotech stocks surged Friday after new details on a closely watched clinical trial lifted hopes that scientists may be close to a treatment for the coronavirus, which continues to maintain its foothold across the globe after emerging a little over three months ago.The IBB, an ETF that tracks biotech’s biggest players, was up more than 2% Friday after health-care publication STAT News revealed early impressions from one of Gilead Sciences’ clinical trials for antiviral drug remdesivir. The University of Chicago found that patients with Covid-19 had “rapid recoveries in fever and respiratory symptoms” and were discharged in less than a week, according to STAT. News that biotech firm Moderna received $483 million in federal funds for its vaccine development also boosted the sector higher.

Read More

Selected Notes From Wall Street Analysts On Applied DNA Sciences, Inc. (APDN)

US Post News | April 16, 2020

On Wednesday, shares of Applied DNA Sciences, Inc. (NASDAQ:APDN) marked $5.76 per share versus a previous $4.55 closing price. With having a 26.59% gain, an insight into the fundamental values of Applied DNA Sciences, Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. APDN showed a rise of 37.47% within its YTD performance, with highs and lows between $2.52 – $33.60 during the period of 52 weeks, compared to the simple moving average of -26.60% in the period of the last 200 days. Maxim Group equity researchers changed the status of Applied DNA Sciences, Inc. (NASDAQ: APDN) shares to a “Buy” rating in the report published on November 14th, 2016. Other analysts, including Maxim Group, also published their reports on APDN shares. Maxim Group repeated the rating from the previous report, marking APDN under “Buy” rating, in the report published on May 13th, 2016. Additionally, APDN shares got another “Buy” rating from Maxim Group, setting a target price of $13 on the company’s shares, according to the report published in October 8th, 2015.

Read More

Events